Evolus (NASDAQ:EOLS) Insider Sells $16,166.15 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,261 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $16,166.15. Following the completion of the transaction, the insider owned 356,821 shares of the company’s stock, valued at $2,551,270.15. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Evolus Price Performance

NASDAQ EOLS traded down $0.24 during trading hours on Monday, reaching $6.66. 742,236 shares of the stock traded hands, compared to its average volume of 1,126,954. The stock has a 50 day simple moving average of $6.91 and a two-hundred day simple moving average of $7.51. Evolus, Inc. has a 1 year low of $5.71 and a 1 year high of $17.12. The company has a market cap of $431.70 million, a price-to-earnings ratio of -7.24 and a beta of 0.87.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to analyst estimates of $91.23 million. Evolus had a negative return on equity of 759.04% and a negative net margin of 20.49%. On average, sell-side analysts forecast that Evolus, Inc. will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Evolus

Several institutional investors have recently added to or reduced their stakes in the company. Manchester Capital Management LLC purchased a new position in shares of Evolus in the second quarter valued at about $26,000. State of Alaska Department of Revenue bought a new stake in shares of Evolus in the third quarter worth about $26,000. Wexford Capital LP bought a new stake in shares of Evolus in the third quarter worth about $37,000. AlphaQuest LLC purchased a new position in Evolus during the 1st quarter valued at about $39,000. Finally, State of Wyoming raised its position in Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company’s stock valued at $45,000 after purchasing an additional 3,409 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on EOLS. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Mizuho reduced their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, December 1st. BTIG Research reissued a “buy” rating and issued a $18.00 price target on shares of Evolus in a research note on Monday, September 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Finally, Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Evolus has a consensus rating of “Moderate Buy” and an average target price of $20.80.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.